IP Verse

Apixaban Formulations - EP3257500

The patent EP3257500 was granted to Bristol Myers Squibb Ireland on Oct 16, 2019. The application was originally filed on Feb 24, 2011 under application number EP17178613A. The patent is currently recorded with a legal status of "Revoked".

EP3257500

BRISTOL MYERS SQUIBB IRELAND
Application Number
EP17178613A
Filing Date
Feb 24, 2011
Status
Revoked
Mar 22, 2024
Grant Date
Oct 16, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKJul 16, 2020TER MEER STEINMEISTER & PARTNERADMISSIBLE
STADA ARZNEIMITTELJul 16, 2020KERNEBECKADMISSIBLE
SANDOZJul 15, 2020KRAUS & LEDERER PARTGMBBADMISSIBLE
INTAS PHARMACEUTICALSJul 15, 2020ACCORD HEALTHCAREWITHDRAWN
KRKAJul 15, 2020HOEFER & PARTNER PATENTANWALTE MBBWITHDRAWN
MEDICHEMJul 14, 2020HAMM & WITTKOPPADMISSIBLE
TEVA PHARMACEUTICALSJul 14, 2020D YOUNGADMISSIBLE
KUTZENBERGER WOLFF & PARTNERJul 13, 2020KUTZENBERGER WOLFF & PARTNERADMISSIBLE
ZENTIVA KSJul 13, 2020HOFFMANN EITLEADMISSIBLE
POLPHARMAJul 2, 2020ELKINGTON AND FIFEADMISSIBLE

Patent Citations (22) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2006069258
DESCRIPTIONUS6967208
OPPOSITIONEP2538925
OPPOSITIONEP3017811
OPPOSITIONUS2006069258
OPPOSITIONUS2006160841
OPPOSITIONUS2007259913
OPPOSITIONUS2009291913
OPPOSITIONUS6967208
OPPOSITIONUS7396932
OPPOSITIONWO2006108643
OPPOSITIONWO2007001385
OPPOSITIONWO2007022165
OPPOSITIONWO2007053904
OPPOSITIONWO2008031782
OPPOSITIONWO2009135947
OPPOSITIONWO2010003811
OPPOSITIONWO2010147978
OPPOSITIONWO2011106478
SEARCHUS2006160841
SEARCHWO2008031782
SEARCHWO2010147978

Non-Patent Literature (NPL) Citations (102) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- G. L. et al., "BCS; Amidon", Pharmaceutical Research, (19950000), vol. 12, pages 413 - 420-
OPPOSITION- Alan Rawle, "BASIC PRINCIPLES OF PARTICLE SIZE ANALYSIS", Malvern Technical Paper, Malvern Instruments Limited, UK, UK, (19930101), no. MRK034, pages 1 - 8, XP002772489-
OPPOSITION- Amidon, Et Al., "A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability", Pharmaceutical Research, (19950101), vol. 12, no. 3, pages 413 - 420, XP055640443-
OPPOSITION- Amidon, Et Al, "Chapter 8", Developing solid oral dosage forms: Pharmaceutical Theory and Practice, Academic Press, (20090101), pages 163 - 167, 414-416, XP055641338-
OPPOSITION- ANNUAR N HAFIZAH HJ; TAN K S; OLOFINJANA A, "EFFECTS OF SAMPLE CONDITIONS IN MULTI-PARTICLE SIZE ANALYSIS USING LASER DIFFRACTION TECHNIQUE", Scientia Bruneiana : official journal of the Faculty of Science, Universiti Brunei Darussalam, (20100000), vol. 11, pages 19 - 26, XP003035190-
OPPOSITION- Anonymous, "<429> Light Diffraction measurement of Particle Size", US pharmacopoeia, USP 38, (20150501), pages 294 - 299, US pharmacopoeia, USP 38, (20191108), XP055640457-
OPPOSITION- Anonymous, "Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation", ClinicalTrials.gov NCT00412984, (20130927), pages 1 - 7, URL: https://clinicaltrials. gov/ct2/show/record/NCT00412984 ?term= NCT00412984&rank= 1, XP055323941-
OPPOSITION- Anonymous, "Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation - Tabular View - ClinicalTrials.gov", ClinicalTrials.gov NCT00412984, (20130927), pages 1 - 7, ClinicalTrials.gov NCT00412984, URL: https://clinicaltrials.gov/ct2/show/record/NCT00412984?term=NCT00412984&rank= 1, (20161129), XP055323941-
OPPOSITION- Anonymous, "A randomized, double-blind palcebo-controlled study of apixaban for the prevention of thromboembolic events in patients undergoing treatment for advanced cancer: a phase 2 pilot study", ClinicalTrials.gov archive of NCT00320255, (20100218), pages 1 - 2, XP055638473-
OPPOSITION- Anonymous, "A randomized, double-blind palcebo-controlled study of apixaban for the prevention of thromboembolic events in patients undergoing treatment for advanced cancer: a phase 2 pilot study", ClinicalTrials.gov, NCT00320255, (20100218), pages 1 - 2, ClinicalTrials.gov, NCT00320255, (20191104), XP055638473-
OPPOSITION- Anonymous, "A safety and efficacy trial evaluating the use of apixaban for the extended treatment of deep vein thrombosis and pulmonary embolism", ClinicalTrials.gov archive, View of NCT00643201, (20100218), pages 1 - 4, XP055638468-
OPPOSITION- Anonymous, "A safety and efficacy trial evaluating the use of apixaban for the extended treatment of deep vein thrombosis and pulmonary embolism", ClinicalTrials.gov, NCT00633893, (20100218), pages 1 - 4, ClinicalTrials.gov, NCT00633893, (20191104), XP055638465-
OPPOSITION- Anonymous, "Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism", ClinicalTrials.gov NCT00633893, (20100218), ClinicalTrials.gov NCT00633893, URL: https://clinicaltrials.gov/archive/NCT00633893/2010_02_18, (20191108), XP055640663-
OPPOSITION- Anonymous, "Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism", ClinicalTrials.gov NCT00633893, (20100218), pages 1 - 4, XP055640663-
OPPOSITION- Anonymous, "Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism", Clinical Trials.gov, NCT00643201, (20100218), Clinical Trials.gov, NCT00643201, URL: https://clinicaltrials.gov/archive/NCT00643201 /2010_02_18, (20191108), XP055640665-
OPPOSITION- Anonymous, "Guidance for Industry Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System", U. S. Department of health and human services food and drug administration center for drug evaluation and research (CDER), (20000800), pages 1 - 16, XP055767942-
OPPOSITION- Anonymous, "Light Diffraction measurement of Particle Size", US pharmacopoeia, USP 38, (20150501), pages 295 - 299, XP055640457-
OPPOSITION- Anonymous, "Micronize", Merriam Webster Dictionary, (20190619), pages 1 - 14, URL: https://www.merriam-webster.com/dictionary/micronize, XP055768538-
OPPOSITION- Anonymous, "Particle size analysis by laser light diffraction", European Pharmacopoeia 8.0, Section 2.9.31, (20100101), pages 333 - 336, XP055421006-
OPPOSITION- Anonymous, "Particle size analysis - laser diffraction methods", International Standard ISO 13320-1, pages 1 - 40, XP055766505-
OPPOSITION- Anonymous, ", Section 2.9.31 - Particle Size Analysis by Laser Light Diffraction", European Pharmacopoeia 6.0, (20070723), pages 311 - 314, XP055638472-
OPPOSITION- Anonymous, "The Biopharmaceutics Classification System (BCS) Guidance", FDA U.S. Food & Drug, (20160101), FDA U.S. Food & Drug, URL: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm128219.htm, (20161006), XP055308403-
OPPOSITION- AULTON, "The design of dosage forms", Pharmaceutics: The Science of Dosage Form Design, (19880000), pages 1 - 13, 135-173, XP055734912-
OPPOSITION- C. FROST et al., "Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects", J. Thromb. Haemost, (20070000), vol. 5, no. 2, page 1, XP055766184-
OPPOSITION- "CHAPTER 10: Tablet Dosage Forms", Rudnic E M; Kottke M K, Modern Pharmaceutics (third edition), (19960000), pages 333 - 359, XP009184716-
OPPOSITION- "Chapter 39", Michael E Aulton, PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, (19880000), pages 647 - 653, XP055317802-
OPPOSITION- David Attwood, Et Al, "Dissolution of drugs", Physical Pharmacy, (20080101), page 7, XP055765090-
OPPOSITION- Deodatt A Wadke, Abu T M Serajuddin, Harold Jacobson, "CHAPTER 1: Preformulation Testing", Deodatt A Wadke, Abu T M Serajuddin, Harold Jacobson, LIEBERMAN H.A.; LACHMAN L.; SCHAWARTZ J.B., Pharmaceutical Dosage Forms: Tablets, US, Marcel Dekker, (19890101), vol. 1, pages 1 - 73, ISBN 978-0-8247-8044-9, XP009184711-
OPPOSITION- Deodatt A Wadke; Abu T M Serajuddin; Harold Jacobson, "CHAPTER 1: Preformulation Testing", Pharmaceutical dosage forms: Tablets, (19890000), vol. 1, pages 1 - 9, XP009184711-
OPPOSITION- "DEVELOPING SOLID ORAL DOSAGE FORMS PHARMACEUTICAL THEORY AND PRACTICE", QIU Y; ET AL, DEVELOPING SOLID ORAL DOSAGE FORMS PHARMACEUTICAL THEORY AND PRACTICE, (20090000), pages 1 - 7, XP003031377-
OPPOSITION- "Dissolution and solibility", Aulton M E, Pharmaceutics The Science of Dosage Form Design, second edition, (20020000), pages 23 - 29, XP055308566-
OPPOSITION- DRESSMAN et al., "The BCS: Where Do We Go from Here?", Pharmaceutical Technology, (20010000), pages 68 - 76, XP055308304-
OPPOSITION- EDWARD RUDNIC, JOSEPH B SCHWARTZ, "ORAL SOLID DOSAGE FORMS", EDWARD RUDNIC, JOSEPH B SCHWARTZ, ALFONSO R GENNARO, REMINGTON'S PHARMACEUTICAL SCIENCES ED.18, US, MACK PUBLISHING CO., (19900101), pages 1633 - 1658, ISBN 0-912734-04-3, XP003032399-
OPPOSITION- EMA Assessment Report for Eliquis®, Procedure No. EMA/H/C/002148, pages 1 - 62-
OPPOSITION- E. RUDNIC, "Oral Solid Dosage Forms", Remington's Pharmaceutical Sciences, (19900000), pages 1633 - 1658, XP002969032-
OPPOSITION- Falbe J., Regitz M., "Zerkleinern", Rompp Lexikon Chemie, (19990000), vol. 6, page 5056, XP055766232-
OPPOSITION- Frost, C., Et Al, "[P-M-665] Apixaban is an oral direct, factor Xa inhibitors: single dose safety, pharnacokinetics and pharmacodynamics in healthy subjects", J. Thromb. Haemost, (20070709), XP055640220-
OPPOSITION- "General notices", Anonymous, European Pharmacopoeia sixth edition, supplement 6.5, (20080000), pages 4759 - 4765, XP055640607-
OPPOSITION- Ghebre-Sellasie, "Particle size reduction processes", Pharmaceutical Extrusion Technoogy, Dekker, (20030101), pages 236 - 238, XP055765195-
OPPOSITION- Gibaldi, "Biopharmaceutics and Clinical Pharmacokinetics", (19910101), page 51, (20161007), XP055308521-
OPPOSITION- Heinz Sucker Et Al., "Pharmazeutische Technologie", Pharmazeutische Technologie, 2. Auflage, Georg Thieme Verlag, (19910101), pages 158 - 161, ISBN 978-3-13-395802-8, XP055308164-
OPPOSITION- Herbert A Lieberman, Et Al, "Preformulation testing", PHARMACEUTICAL DOSAGE FORMS. Vol 1, 2 nd ed., rev. and exp., Marcel Dekker, (19890101), pages 1 - 6, PHARMACEUTICAL DOSAGE FORMS. Vol 1, 2 nd ed., rev. and exp., (20170703), XP055387119-
OPPOSITION- James Swarbrick Et Al., "Tablet Formulation", Encyclopedia of Pharmaceutical Technology, 2nd edition, (20020101), pages 2701 - 2712, ISBN 978-0-8247-2824-3, XP055308380-
OPPOSITION- JEAN-LOUIS SALAGER, "Surfactants, Types and Uses", Laboratory of formulation , interfaces Rheology and processes, XP055256074-
OPPOSITION- Jennifer Dressman, "The BCS: Where Do We Go from Here?", Pharm Tech, (20010701), pages 68 - 76, XP055308304-
OPPOSITION- Joseph P. Remington, "Dissolution", Joseph P. Remington, Gennaro Alfonso R., Remington: the science and practice of pharmacy, Easton, Pennsylvania, Mack Publishing Company, (19950101), page 2pp, 595, ISBN 978-0-912734-04-0, XP055282825-
OPPOSITION- J. SWARBRICK et al., "Tablet Formulation", Encyclopedia of Pharmaceutical Technology, (20020000), vol. 3, pages 2701 - 2712, XP055308380-
OPPOSITION- K. H. BAUER et al., "Pharmazeutische Technologie", Pharmazeutische Technologie, Frankfurt, (19970000), pages 209 - 210 , 365, XP055308591-
OPPOSITION- Kurt H. Bauer Et Al., "Chapter 6 and 7", Pharmazeutische Technologie, (19970101), pages 178, 208 - 211, ISBN 978-3-7741-0638-3, XP055308166-
OPPOSITION- Kurt H, Bauer, Et Al, "Löslichkeit", Pharmazeutische Technologie, 5. Auflage, (19970101), pages 209 - 210, 365, ISBN 978-3-437-25630-1, XP055641330-
OPPOSITION- "Light Diffraction Measurement of Particle Size", US Pharmacopeia, (20150501), pages 294 - 299, XP055241392-
OPPOSITION- L. LACHMANN et al., "Factors affecting drug absorption", The Theory and Practice of Industrial Pharmacy, third edition, Philadelphia, (19860000), pages 221 - 222, XP055733214-
OPPOSITION- L. Lachmann Et Al., "The Theory and Practice of Industrial Pharmacy", The Theory and Practice of Industrial Pharmacy, (19860101), pages 221 - 222, XP055308588-
OPPOSITION- Malvern, "Mastersizer SA, Mastersizer 2000 and Mastersizer 3000: Method transfer - how to get the same results on all three systems", Malvern, (2015), pages 1 - 65-
OPPOSITION- M. E. Aulton, M. Ashford, "Bioavailability - physicochemical and dosage form factors", Aulton's Pharmaceutics, The Design and Manufacture of Medicines, 3rd edition, (20070101), pages 286 - 449, ISBN 978-0-443-10107-6, XP055308287-
OPPOSITION- M. E. Aulton, "Pharmaceutics: The Science of Dosage Form Design", Pharmaceutical Formulation, (20020101), pages 113 - 138, XP055523140-
OPPOSITION- Michael E Aulton, "The design of Dosage Forms", Pharmaceutics: The Science of Dosage Form Design, Churchill, (19880101), pages 1 - 56, XP055765151-
OPPOSITION- M.R. Lassen, B. L. Davidson, A. Gallus, G. Pineo, J. Ansell, D . Deitchman, "The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement1", Journal of Thrombosis and Haemostasis, (20070101), vol. 5, pages 2368 - 2375, XP055754069-
OPPOSITION- M R Lassen , B L Davidson, A Gallus, G Pineo, J Ansell, D Deitchman, "The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement", The New England Journal of Medicine, (20090000), vol. 361, pages 594 - 604, XP055766247-
OPPOSITION- Rakesh K Tekade, "Effect of polymorphism on different drug properties", Dosage Form Design Parameters , Colume II, Academic Press, (20180101), pages 42 - 48, XP055765175-
OPPOSITION- Rong Liu, "Particle size reduction methods", Water-Insuble Drug Formulation, CRC Press, (20080101), pages 482 - 484, XP055765200-
OPPOSITION- Rowe R C;, Et Al, "HYDROXYPROPYL CELLULOSE -sodium lauryl sulfate", Handbook of Pharmaceutical Excipients, (20030101), pages 289 - 568-570, Handbook of Pharmaceutical Excipients, (20160406), XP055263237-
OPPOSITION- Rudnic E M, Kottke M K, "CHAPTER 10: Tablet Dosage Forms", Rudnic E M, Kottke M K, Gilbert S Banker, Christopher T Rhodes (eds.), Modern Pharmaceutics (third edition), Marcel Dekker, (19960101), pages 333 - 394, ISBN 0-8247-9371-4, XP009184716-
OPPOSITION- Rudnic E., Schwartz D. Joeseph, "Chapter 89", Remington's Pharmaceutical Sciences eighteenth edition, (19900000), pages 1633 - 1658, XP055768460-
OPPOSITION- Serno, "Literatur", Granulieren, (20070101), pages 144 - 145, XP055765053-
OPPOSITION- Stojanovic Z., Et Al, "Determination of particle size distribution by laser diffraction", Technics-New Materials 21, (20120101), pages 11 - 20, Technics-New Materials 21, URL: http://www.itn.sanu.ac.rs/images/Stojanovic_Technics_67_11-20.pdf, (20150319), XP055177703-
OPPOSITION- Sucker, Et Al, "3.4.2 Feste Arzneiformen", Pharmazeutische Technologie, Georg Thieme verlag, (19910101), pages 158 - 161, XP055640651-
OPPOSITION- U. V. BANAKAR, "Factors That Influence Dissolution Testing", Pharmaceutical Dissolution Testing, (19920000), pages 136 - 137 and 144-145, XP055308585-
OPPOSITION- U. V. Banakar, "Polymorphism", Pharmaceutical Dissolution Testing, Marcel Dekker, (19920101), pages 136, 137, 144 - 145, XP055641322-
OPPOSITION- "Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on BCS", Guidance for Industry, (20000000), XP003031467-
OPPOSITION- W.A. Ritschel, A.Bauer-Brandl, "Die Tablette Handbuch der Entwicklung, Herstellung und Qualitätssicherung /Passage/", Die Tablette Handbuch der Entwicklung, Herstellung und Qualitätssicherung, Editio Cantor Verlag, (20020101), pages 2pp, 122, 226 - 266, XP055754371-
OPPOSITION- W. A. RITSCHEL et al., "Chapter 3 & 4", Die Tablette Handbuch der Entwicklung, Herstellung und Qualitatssicherung, (20020000), pages 235 - 241 , 256-259, XP055308574-
OPPOSITION- Yasuhiro Tsume, Gordon L Amidon, "The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation", Molecular Pharmaceutics, vol. 7, no. 4, pages 1235 - 1243, XP055308518-
OPPOSITION- Zheng, "overview of dry granulation processes and equipment design", Formulation and analytical development for low-dose oral drug products, Wiley, (20090101), pages 119 - 122, XP055765171-
OPPOSITION- Z. STOJANOVIC et al., "Determination of particle size distributions by laser diffraction", Technics-New Materials, (20120000), vol. 21, pages 11 - 20, XP055307143-
OPPOSITION- Z. STOJANOVIC et al., "Determination of Particle Size Distributions by Laser Diffraction", Technics-New Materials, (20120000), vol. 21, pages 11 - 20, XP055307143-
OPPOSITION- Z. STOJANOVI? et al., "Determination of Particle Size Distributions by Laser Diffraction", Technics - New Materials, (20120000), vol. 21, pages 11 - 20, XP055307143-
OPPOSITION- J.B. Dressman, G.L. Amidon, D. Fleisher, "Absorption Potential: Estimating the Fraction Absorbed for Orally Administered Compounds", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, US, US, (19850501), vol. 74, no. 5, doi:10.1002/jps.2600740523, ISSN 0022-3549, pages 588 - 589, XP055308397
OPPOSITION- S. Stegemann, F. Leveiller, D. Franchi, H. De Jong, H. Lindén, "When poor solubility becomes an issue: From early stage to proof of concept", European Journal of Pharmaceutical Sciences, Elsevier Amsterdam, NL, NL, (20070801), vol. 31, no. 5, doi:10.1016/j.ejps.2007.05.110, ISSN 0928-0987, pages 249 - 261, XP055765093
OPPOSITION- Stegemann S; Leveiller F; Franchi D; De Jong H; Lindén H, "When poor solubility becomes an issue: From early stage to proof of concept", Eur J Pharm Sci, (20070801), vol. 31, pages 249 - 261, XP055765093
OPPOSITION- Stegemann, S. Leveiller, F. Franchi, D. de Jong, H. Linden, H., "When poor solubility becomes an issue: From early stage to proof of concept", European Journal of Pharmaceutical Sciences, Elsevier Amsterdam, NL, NL, (20070719), vol. 31, no. 5, doi:10.1016/j.ejps.2007.05.110, ISSN 0928-0987, pages 249 - 261, XP022163590
OPPOSITION- Papadopoulou, V. ; Valsami, G. ; Dokoumetzidis, A. ; Macheras, P., "Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): Theoretical basis and practical examples", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, NL, (20080901), vol. 361, no. 1-2, doi:10.1016/j.ijpharm.2008.05.021, ISSN 0378-5173, pages 70 - 77, XP023316061
OPPOSITION- Alain Chamayou, John A. Dodds, "Chapter 8 Air Jet Milling", Handbook of Powder Technology, Elsevier B.V, (20070101), vol. 12, pages 421 - 435, doi:10.1016/S0167-3785(07)12011-X, ISSN 0167-3785, ISBN 978-0-444-51871-2, XP055765180
OPPOSITION- CHAMAYOU A. et al., "Air Jet Milling", Handbook of Powder Technol- ogy, (20070000), vol. 12, doi:10.1016/S0167-3785(07)12011-X, pages 421 - 435, XP055765180
OPPOSITION- Henning H Blume, Barbara S Schug, "The biopharmaceutics classification system (BCS): Class III drugs — better candidates for BA/BE waiver?", European Journal of Pharmaceutical Sciences, Elsevier Amsterdam, NL, NL, (19991201), vol. 9, no. 2, doi:10.1016/S0928-0987(99)00076-7, ISSN 0928-0987, pages 117 - 121, XP055308358
OPPOSITION- H. H. BLUME et al., "The biopharmaceutics classification system (BCS): Class III drugs better candidates for BA / BE waiver?", European Journal of Pharmaceutical Sciences, (19990000), vol. 9, doi:10.1016/S0928-0987(99)00076-7, pages 117 - 121, XP055308358
OPPOSITION- D. J. PINTO et al., "Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1- yl)phenyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban , BMS-562247) , a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa", J. Med. Chem., (20070000), vol. 50, doi:10.1021/jm070245n, pages 5339 - 5356, XP007915445
OPPOSITION- Pinto D, et al, "Discovery of 1-[4-(Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa", Journal of Medicinal Chemistry, American Chemical Society, (20070101), vol. 50, doi:10.1021/jm070245n, ISSN 0022-2623, pages 5339 - 5356, XP007915445
OPPOSITION- PINTO et al., "Discovery of 1-(4-Methoxyphenyl", J. Med Chem, (20070000), vol. 50, doi:10.1021/jm070245n, pages 5339 - 5356, XP007915445
OPPOSITION- Gordon L AmidonHans LennernäsVinod P ShahJohn R Crison, "A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability", Pharmaceutical Research, (19950000), vol. 12, pages 413 - 420, XP009035978
OPPOSITION- Lawrence X Yu et al, "Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions", Pharmaceutical Research, (20020701), vol. 19, no. 7, doi:10.1023/a:1016473601633, pages 921 - 925, XP055308362
OPPOSITION- L. X. YU et al., "Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions1", Pharmaceutical Research, (20020700), vol. 19, no. 7, doi:10.1023/a:1016473601633, pages 921 - 925, XP055308362
OPPOSITION- Christopher B Granger; John H Alexander; John J V Mcmurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; Cecilia Bahit M; Rafael Diaz; Donald Easton J; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin, "Apixaban versus warfarin in patients with atrial fibrillation", The New England Journal of Medicine, N Engl J Med, (20110000), vol. 365, pages 981 - 992, XP055308595
OPPOSITION- P. BOWEN, "Particle Size Distribution Measurement from Millimeters to Nanometers and from Rods to Platelets", Journal of Dispersion Science and Technology, (20020000), vol. 23, no. 5, doi:10.1081/DIS-120015368, pages 631 , 632 , 647 - 652, XP009102859
OPPOSITION- Georgia Charkoftaki, Et Al, "Biopharmaceutical Classification Based on Solubility and Dissolution: A Reappraisal of Criteria for Hypothesis Models in the Light of the Experimental Observations", BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, NORDIC PHARMACOLOGICAL SOCIETY, COPENHAGEN, DK, COPENHAGEN, DK, (20100301), vol. 106, no. 3, doi:10.1111/j.1742-7843.2009.00506.x, ISSN 1742-7835, pages 168 - 172, XP055765163
OPPOSITION- TURPIE ALEXANDER G G, "Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases", Arterioscler Thromb Vasc Biol., (20070000), vol. 27, no. 6, pages 1238 - 1247, XP002672841
OPPOSITION- APPRAISE STEERING COMMITTEE AND INVESTIGATORS, "Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination with Antiplatelet After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial", Circulation, (20090000), vol. 119, no. 22, doi:10.1161/CIRCULATIONAHA.108.832139, pages 2877 - 85, XP055636386
OPPOSITION- APPRAISE STEERING COMMITTEE AND INVESTIGATORS, "Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome : Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial", Circulation, (20090000), vol. 119, pages 2877 - 2855, XP055636386
OPPOSITION- Yu Lawrence X et al, "Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs", AAPS PharmSci, Springer New York, New York, New York, (20010901), vol. 3, no. 3, doi:10.1208/ps030324, pages 86 - 92, XP035718572
OPPOSITION- Cook Jack; Addicks William; Wu Yunhui Henry, "Application of the Biopharmaceutical Classification System in Clinical Drug Development—An Industrial View", The AAPS Journal, Springer US, Boston, Boston, (20080524), vol. 10, no. 2, doi:10.1208/s12248-008-9036-5, pages 306 - 310, XP035718954
OPPOSITION- Kylie Lepic, Mark Crowther, "New Anticoagulants for the Prevention of Thromboembolism", Current Pharmaceutical Design, Bentham Science Publishers, NL, NL, (20101001), vol. 16, no. 31, doi:10.2174/138161210793563437, ISSN 1381-6128, pages 3472 - 3474, XP055308375
OPPOSITION- STORTI F, BALSAMO F, "Particle size distributions by laser diffraction: sensitivity of granular matter strength to analytical operating procedures", SOLID EARTH, Copernicus GmbH, DE, DE, (20100419), vol. 1, doi:10.5194/se-1-25-2010, ISSN 1869-9510, pages 25 - 48, XP003027683

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents